Cite
HARVARD Citation
Lerebours, F. et al. (n.d.). 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials. European journal of cancer. pp. S19-. [Online].